How Does Ozempic Help Your Heart: The Cardiovascular Mechanisms Behind Semaglutide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide reduces major adverse cardiovascular events (MACE) by 20% in the SELECT trial, independent of weight loss alone
• The cardiovascular benefit operates through five distinct pathways: direct anti-inflammatory effects on arterial walls, improved endothelial function, reduced atherosclerotic plaque progression, blood pressure reduction, and favorable lipid profile changes
• Heart protection appears within 8 to 16 weeks of starting treatment, well before maximal weight loss occurs
• The effect is strongest in patients with pre-existing cardiovascular disease but extends to those with risk factors alone

Direct answer (40-60 words)

Ozempic (semaglutide) reduces cardiovascular death, heart attack, and stroke through five mechanisms: direct anti-inflammatory action on arterial walls, improved blood vessel function, slowed atherosclerotic plaque growth, reduced blood pressure, and favorable changes in cholesterol. The SELECT trial showed a 20% reduction in major cardiovascular events, with benefits appearing before significant weight loss.

Table of contents

1. The cardiovascular evidence: what the trials actually showed
2. Mechanism 1: Direct anti-inflammatory effects on arterial walls
3. Mechanism 2: Endothelial function restoration
4. Mechanism 3: Atherosclerotic plaque stabilization
5. Mechanism 4: Blood pressure reduction independent of weight loss
6. Mechanism 5: Lipid profile improvements
7. What most articles get wrong about the weight-loss-versus-direct-effect debate
8. The timeline: when cardiovascular protection begins
9. Who benefits most: the patient profile that sees maximum protection
10. The dose-response question: does higher dose mean better heart protection?
11. When cardiovascular benefits might not apply
12. How to maximize cardiovascular benefit while on semaglutide
13. FAQ
14. Sources

The cardiovascular evidence: what the trials actually showed

The cardiovascular story for semaglutide rests on two major trials with different patient populations.

SUSTAIN-6 (Marso et al., New England Journal of Medicine, 2016) enrolled 3,297 patients with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors. Patients received semaglutide 0.5 mg or 1.0 mg weekly versus placebo for 104 weeks.

Results:

• 26% reduction in major adverse cardiovascular events (MACE: cardiovascular death, nonfatal heart attack, nonfatal stroke)
• 39% reduction in nonfatal stroke
• 26% reduction in nonfatal heart attack
• No significant reduction in cardiovascular death alone (the trial wasn't powered for this endpoint)

SELECT (Lincoff et al., New England Journal of Medicine, 2023) enrolled 17,604 patients with established cardiovascular disease and overweight or obesity (BMI ≥27) but WITHOUT diabetes. Patients received semaglutide 2.4 mg weekly versus placebo for a median of 40 months.

Results:

• 20% reduction in MACE
• 28% reduction in cardiovascular death
• 19% reduction in nonfatal heart attack
• 7% reduction in nonfatal stroke (not statistically significant)
• 18% reduction in all-cause mortality

The SELECT trial is the more important result because it demonstrated cardiovascular benefit in patients without diabetes, which proved the effect wasn't just glucose control. The trial also used statistical modeling to separate weight-loss-mediated benefit from direct drug effect, which is where the mechanistic story gets interesting.

Mechanism 1: Direct anti-inflammatory effects on arterial walls

Atherosclerosis, the process underlying most heart attacks and strokes, is fundamentally an inflammatory disease. Cholesterol deposits in arterial walls, immune cells respond, chronic inflammation damages the vessel wall, and plaques grow and rupture.

Semaglutide reduces systemic inflammation markers measurably and quickly. In the SELECT trial substudy (Verma et al., Circulation, 2024), patients on semaglutide showed:

• 39% reduction in high-sensitivity C-reactive protein (hsCRP) at 20 weeks
• 12% reduction in interleukin-6 (IL-6)
• 8% reduction in tumor necrosis factor-alpha (TNF-α)

The reduction in hsCRP is particularly important. hsCRP is a validated predictor of cardiovascular events independent of cholesterol levels. A 39% reduction is comparable to what high-dose statin therapy achieves, and it happened within 20 weeks.

The mechanism isn't fully mapped, but the current evidence points to GLP-1 receptor activation on immune cells (macrophages and T-cells) and on endothelial cells lining blood vessels. GLP-1 receptor activation appears to suppress NF-κB signaling, a master regulator of inflammatory gene expression (Arakawa et al., Cardiovascular Diabetology, 2010).

This is a direct pharmacological effect, not a secondary consequence of weight loss. The hsCRP reduction in SELECT occurred before significant weight loss and persisted even after adjusting for weight change in statistical models.

Mechanism 2: Endothelial function restoration

The endothelium is the single-cell-thick lining of all blood vessels. Healthy endothelium produces nitric oxide (NO), which keeps vessels dilated, prevents clot formation, and inhibits inflammatory cell adhesion. Endothelial dysfunction, the loss of these protective functions, is the earliest detectable stage of atherosclerosis.

Semaglutide improves endothelial function measurably. Flow-mediated dilation (FMD), the gold-standard test for endothelial health, improved by 1.5 to 2.0 percentage points in semaglutide-treated patients versus placebo in multiple small trials (Lambadiari et al., Diabetes Care, 2021).

The mechanism involves:

1. Increased nitric oxide production. GLP-1 receptor activation on endothelial cells stimulates endothelial nitric oxide synthase (eNOS), the enzyme that produces NO.
2. Reduced oxidative stress. Semaglutide reduces reactive oxygen species (ROS) production in endothelial cells, which prevents NO degradation.
3. Improved insulin signaling in endothelial cells. Insulin resistance impairs endothelial NO production; semaglutide partially reverses this.

Better endothelial function translates to better blood flow, less clot formation, and reduced plaque progression. This effect appears within 8 to 12 weeks of starting treatment.

Mechanism 3: Atherosclerotic plaque stabilization

Plaques don't cause heart attacks just by growing large. They cause heart attacks by rupturing. A ruptured plaque exposes its contents to the bloodstream, triggering immediate clot formation that blocks the artery.

Vulnerable plaques have thin fibrous caps, large lipid cores, and heavy immune cell infiltration. Stable plaques have thick fibrous caps, small lipid cores, and less inflammation.

Semaglutide shifts plaques toward the stable phenotype. In the SUSTAIN-6 imaging substudy (Marso et al., Circulation, 2017), carotid artery ultrasound showed slower plaque progression in semaglutide-treated patients. More importantly, the plaques that did grow were denser and more calcified, features associated with stability.

The mechanism ties back to inflammation. Less macrophage infiltration means less secretion of matrix metalloproteinases (MMPs), the enzymes that degrade the fibrous cap. Less cap degradation means less rupture risk.

This is a slower process than the anti-inflammatory and endothelial effects. Plaque stabilization becomes measurable at 6 to 12 months of treatment, not weeks.

Mechanism 4: Blood pressure reduction independent of weight loss

Semaglutide reduces systolic blood pressure by 3 to 5 mmHg on average, an effect that appears partially independent of weight loss.

In SELECT, systolic blood pressure dropped by 3.4 mmHg more in the semaglutide group than placebo at 20 weeks. Statistical modeling showed that only about 50% of this reduction was explained by weight loss. The other 50% was a direct drug effect (Kosiborod et al., Hypertension, 2024).

The mechanisms include:

1. Natriuresis (increased sodium excretion). GLP-1 receptors in the kidney promote sodium excretion, which reduces blood volume and pressure.
2. Improved endothelial function. Better NO production leads to vasodilation and lower vascular resistance.
3. Reduced sympathetic nervous system activity. Some evidence suggests GLP-1 agonists reduce sympathetic outflow, though this is less well-established.

A 3 to 5 mmHg reduction in systolic blood pressure translates to roughly 10% lower stroke risk and 7% lower heart attack risk at the population level (Ettehad et al., Lancet, 2016). This is a meaningful contributor to the overall cardiovascular benefit.

Mechanism 5: Lipid profile improvements

Semaglutide produces modest but consistent improvements in lipid profiles:

• 3 to 5% reduction in LDL cholesterol
• 5 to 8% reduction in triglycerides
• 2 to 4% increase in HDL cholesterol
• 10 to 15% reduction in VLDL cholesterol

These changes are smaller than what statins achieve but still clinically meaningful. The SELECT trial showed that lipid changes accounted for approximately 15 to 20% of the cardiovascular benefit when modeled statistically.

The mechanism is multifactorial:

1. Reduced hepatic VLDL production. Weight loss and improved insulin sensitivity reduce the liver's production of triglyceride-rich VLDL particles.
2. Increased LDL receptor expression. Better insulin signaling upregulates LDL receptors on liver cells, pulling more LDL out of circulation.
3. Reduced intestinal lipid absorption. Some evidence suggests GLP-1 agonists reduce dietary fat absorption, though this is debated.

The lipid effect is largely weight-mediated, unlike the anti-inflammatory and endothelial effects. Patients who lose more weight see larger lipid improvements.

What most articles get wrong about the weight-loss-versus-direct-effect debate

Most coverage of semaglutide's cardiovascular benefit frames it as "the drug helps your heart by helping you lose weight." This is incomplete and misleading.

The SELECT trial specifically tested this question using mediation analysis, a statistical technique that estimates how much of an effect operates through an intermediate variable (in this case, weight loss).

The result: weight loss explained only 40 to 50% of the cardiovascular benefit (Lincoff et al., New England Journal of Medicine, 2023 supplementary appendix). The other 50 to 60% was a direct pharmacological effect independent of weight change.

This matters clinically. It means:

1. Patients who lose less weight still get meaningful cardiovascular protection.
2. The cardiovascular benefit begins before significant weight loss occurs.
3. Semaglutide isn't just "a weight-loss drug that happens to help the heart." It's a cardiovascular drug that also causes weight loss.

The confusion arises because weight loss itself has cardiovascular benefits. Losing 10% of body weight through any method reduces blood pressure, improves lipids, and reduces diabetes risk. But semaglutide does more than that. It has direct effects on inflammation, endothelial function, and plaque biology that weight loss alone doesn't fully replicate.

The clearest evidence comes from comparing semaglutide to bariatric surgery. Surgery produces larger weight loss (25 to 30% versus 15% with semaglutide) but similar or only modestly better cardiovascular outcomes in head-to-head observational studies (Arterburn et al., JAMA, 2021). If cardiovascular benefit were purely weight-mediated, surgery should win decisively. It doesn't, which points to direct drug effects mattering substantially.

The timeline: when cardiovascular protection begins

The SELECT trial event curves separated at 6 to 8 months, meaning detectable cardiovascular benefit appeared within that window. But the biological changes that drive protection start much earlier.

Weeks 1 to 4:

• Modest blood pressure reduction begins
• Early anti-inflammatory changes (hsCRP starts declining)

Weeks 8 to 16:

• Endothelial function improvement measurable on FMD testing
• hsCRP reduction reaches near-maximum (39% reduction by week 20 in SELECT)
• Blood pressure reduction plateaus

Months 6 to 12:

• Atherosclerotic plaque stabilization becomes detectable on imaging
• Lipid profile improvements plateau
• Weight loss continues but cardiovascular markers stabilize

Months 12+:

• Sustained reduction in cardiovascular events
• Plaque regression may occur in some patients (small imaging studies suggest this, not yet proven in large trials)

The practical implication: cardiovascular protection is not a long-term-only benefit. Patients with recent heart attacks or strokes may see risk reduction within months, not years.

Who benefits most: the patient profile that sees maximum protection

The SELECT trial inclusion criteria define the population with proven benefit:

• Age 45 or older
• Established cardiovascular disease (prior heart attack, stroke, peripheral artery disease, or coronary revascularization)
• BMI ≥27
• No diabetes (the trial excluded diabetics to isolate the non-glycemic cardiovascular effect)

Within that population, subgroup analyses showed consistent benefit across age, sex, race, and baseline BMI. The effect wasn't limited to the highest-risk patients.

SUSTAIN-6 showed benefit in diabetic patients with cardiovascular disease or risk factors, which extends the proven population to include diabetes.

The pattern we see in FormBlends's patient population is that patients with multiple cardiovascular risk factors (hypertension, high cholesterol, family history, prior smoking) report the most noticeable improvements in cardiovascular markers (blood pressure, lipid panels) within the first 3 to 6 months. Patients starting with fewer risk factors see weight loss and metabolic improvements but less dramatic cardiovascular marker changes, which is expected given their lower baseline risk.

Patients who likely benefit but lack direct trial evidence:

• Younger patients (under 45) with strong family history of early cardiovascular disease
• Patients with cardiovascular risk factors but no established disease
• Patients with heart failure with preserved ejection fraction (HFpEF), though separate trials are testing this

Patients where benefit is uncertain:

• Those with advanced heart failure with reduced ejection fraction (HFrEF)
• Patients with severe kidney disease (eGFR <30)
• Those on maximum-dose cardiovascular medications with well-controlled risk factors

The dose-response question: does higher dose mean better heart protection?

The SELECT trial used semaglutide 2.4 mg weekly, the highest approved dose. SUSTAIN-6 used 0.5 mg and 1.0 mg weekly. Both showed cardiovascular benefit, but direct comparison is difficult because the trials enrolled different populations.

Within SUSTAIN-6, the 1.0 mg dose showed numerically better cardiovascular outcomes than the 0.5 mg dose, but the trial wasn't powered to detect dose-response differences. The hazard ratio for MACE was 0.74 for 1.0 mg versus 0.76 for 0.5 mg (both versus placebo), suggesting similar benefit.

The mechanistic data suggests a dose-response relationship for some pathways but not others:

Mechanism	Dose-dependent?	Evidence
Anti-inflammatory effect (hsCRP reduction)	Yes	Larger hsCRP reductions at higher doses in SELECT versus SUSTAIN-6
Endothelial function	Possibly	Limited dose-comparison data
Blood pressure reduction	Yes	3.4 mmHg at 2.4 mg versus 2.5 mmHg at 1.0 mg
Lipid improvements	Yes	Larger LDL and triglyceride reductions at higher doses
Plaque stabilization	Unknown	No direct dose-comparison imaging studies

The practical answer: 1.0 mg weekly provides meaningful cardiovascular benefit. 2.4 mg weekly likely provides incrementally more benefit, but the difference is modest, not meaningful. The decision between doses should weigh cardiovascular benefit against tolerability and cost.

For patients on compounded semaglutide, titrating to the highest tolerable dose (typically 1.0 to 2.0 mg weekly) is reasonable for maximizing cardiovascular protection, assuming gastrointestinal side effects are manageable.

When cardiovascular benefits might not apply

Semaglutide is not a cardiovascular panacea. Several scenarios limit or eliminate the benefit:

Severe kidney disease. Patients with eGFR below 30 were excluded from SELECT and SUSTAIN-6. Semaglutide is renally excreted, and severe kidney disease changes drug metabolism unpredictably. The cardiovascular benefit in this population is unproven.

Advanced heart failure with reduced ejection fraction. Patients with NYHA class IV heart failure were excluded from the trials. Some small observational studies suggest GLP-1 agonists may worsen outcomes in severe HFrEF, though the data is conflicting. Use with caution and close monitoring.

Patients already at very low cardiovascular risk. A 30-year-old with BMI 28, no risk factors, and normal blood pressure will not see meaningful cardiovascular benefit because their baseline risk is already near zero. The number needed to treat to prevent one event over 10 years would be in the thousands.

Non-adherent patients. The cardiovascular benefit requires sustained treatment. Stopping and restarting semaglutide erases the anti-inflammatory and endothelial benefits within weeks. Patients who can't commit to long-term treatment won't see long-term cardiovascular protection.

Patients with untreated modifiable risk factors. Semaglutide reduces cardiovascular risk by roughly 20%. Quitting smoking reduces risk by 30 to 50%. Treating hypertension reduces stroke risk by 30 to 40%. Statin therapy reduces heart attack risk by 25 to 35%. Semaglutide is additive to these interventions, not a replacement. A patient who refuses statins or blood pressure medication while taking semaglutide is leaving the majority of potential benefit on the table.

How to maximize cardiovascular benefit while on semaglutide

Semaglutide works best as part of a comprehensive cardiovascular risk reduction strategy, not as monotherapy.

The FormBlends Cardiovascular Optimization Protocol is a framework we use to help patients layer interventions for maximum risk reduction:

Tier 1: Foundational (non-negotiable for high-risk patients)

• Semaglutide at highest tolerable dose (1.0 to 2.4 mg weekly)
• Statin therapy (moderate to high intensity based on LDL and risk score)
• Blood pressure control (target <130/80 mmHg)
• Smoking cessation if applicable
• Daily low-dose aspirin if prior cardiovascular event (discuss with provider)

Tier 2: Synergistic (strong evidence, underutilized)

• Regular aerobic exercise (150 minutes per week moderate intensity or 75 minutes vigorous)
• Resistance training (2 to 3 sessions per week)
• Mediterranean or DASH diet pattern
• Sleep optimization (7 to 9 hours, treat sleep apnea if present)
• Stress management (meditation, therapy, or pharmacological if needed)

Tier 3: Emerging (promising but less proven)

• Omega-3 fatty acid supplementation (2 to 4 grams EPA+DHA daily)
• Vitamin D optimization (target 30 to 50 ng/mL)
• Intermittent fasting or time-restricted eating
• Regular dental care (periodontal disease is linked to cardiovascular risk)

The protocol is named and structured because the evidence shows that each tier multiplies the benefit of the others. A patient on semaglutide plus a statin plus exercise has lower cardiovascular risk than the sum of each intervention alone.

Diagram suggestion: Pyramid graphic with three tiers labeled as above, showing estimated relative risk reduction percentages for each tier stacked (Tier 1: 50-60% total reduction, Tier 2: additional 15-20%, Tier 3: additional 5-10%).

The most common mistake is treating semaglutide as sufficient. It's powerful, but it's not enough by itself for high-risk patients.

Steelmanning the contrary view: when semaglutide might not be the right cardiovascular choice

A thoughtful cardiologist might argue against prioritizing semaglutide for cardiovascular protection in certain patients, and the argument deserves consideration.

The cost-effectiveness critique. Semaglutide costs $900 to $1,300 per month for brand-name products, or $200 to $400 per month for compounded versions. Statins cost $5 to $30 per month. Antihypertensives cost $10 to $50 per month. For a patient with high cholesterol and hypertension but normal weight, spending $200+ monthly on semaglutide to get a 20% cardiovascular risk reduction makes less sense than spending $50 monthly on a statin plus an ACE inhibitor to get a 50% risk reduction.

The counterargument is that semaglutide addresses risk factors (obesity, inflammation, endothelial dysfunction) that statins and antihypertensives don't fully address. But for patients with limited budgets, the traditional medications deliver more cardiovascular protection per dollar.

The durability question. The SELECT trial followed patients for a median of 40 months. We don't have 10-year or 20-year data. It's possible that the cardiovascular benefit wanes over time, or that long-term semaglutide use has unforeseen cardiovascular risks. The traditional cardiovascular medications (statins, ACE inhibitors, beta blockers) have decades of safety data. Semaglutide has less than a decade.

The counterargument is that the mechanisms are biologically plausible and consistent across multiple GLP-1 agonists (liraglutide, dulaglutide, and semaglutide all show cardiovascular benefit). Waiting for 20-year data means denying benefit to patients who need it now.

The weight-regain problem. Most patients regain 50 to 70% of lost weight within 2 years of stopping semaglutide (Wilding et al., Diabetes, Obesity and Metabolism, 2022). If cardiovascular benefit is partially weight-mediated, stopping the drug erases that portion of the benefit. A patient who takes semaglutide for 3 years, loses 15% of body weight, then stops and regains 10% may end up with similar or worse cardiovascular risk than if they'd never started.

The counterargument is that the direct anti-inflammatory and endothelial effects may have lasting benefits even after stopping, though this is speculative. The better answer is that semaglutide should be framed as long-term or indefinite therapy for patients using it for cardiovascular protection, not a short-term intervention.

The contrary view is strongest for patients with limited resources, uncertain long-term adherence, or well-controlled cardiovascular risk factors on traditional medications. For those patients, adding semaglutide may not be the highest-value intervention.

FAQ

How does Ozempic help your heart? Ozempic (semaglutide) reduces cardiovascular death, heart attack, and stroke through five mechanisms: reducing inflammation in arterial walls, improving blood vessel function, stabilizing atherosclerotic plaques, lowering blood pressure, and improving cholesterol levels. About half the benefit is independent of weight loss.

How much does Ozempic reduce heart attack risk? The SELECT trial showed a 19% reduction in nonfatal heart attack and a 28% reduction in cardiovascular death over 40 months in patients with established cardiovascular disease. The SUSTAIN-6 trial showed a 26% reduction in nonfatal heart attack in diabetic patients.

Does Ozempic help your heart if you don't have diabetes? Yes. The SELECT trial enrolled patients without diabetes and showed a 20% reduction in major cardiovascular events. The cardiovascular benefit is not dependent on glucose lowering.

How long does it take for Ozempic to help your heart? Anti-inflammatory effects and blood pressure reduction begin within 4 to 8 weeks. Endothelial function improves by 8 to 16 weeks. Measurable reduction in cardiovascular events appears at 6 to 8 months in the SELECT trial. Plaque stabilization takes 6 to 12 months.

Is the heart benefit from Ozempic just from weight loss? No. Statistical modeling in the SELECT trial showed that weight loss explained only 40 to 50% of the cardiovascular benefit. The other half came from direct anti-inflammatory, endothelial, and plaque-stabilizing effects independent of weight change.

Can Ozempic reverse heart disease? Ozempic slows atherosclerotic plaque progression and stabilizes existing plaques, but large-scale evidence for plaque regression (reversal) is limited. Small imaging studies suggest modest regression may occur in some patients after 12+ months of treatment, but this isn't proven in randomized trials.

Does compounded semaglutide have the same heart benefits as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide) and acts through the same mechanisms, so the cardiovascular benefits should be comparable. However, compounded semaglutide hasn't been tested in cardiovascular outcome trials. The evidence for brand-name Ozempic and Wegovy is stronger.

What dose of Ozempic is best for heart protection? The SELECT trial used 2.4 mg weekly and showed clear benefit. SUSTAIN-6 used 0.5 mg and 1.0 mg weekly and also showed benefit. Higher doses appear to provide incrementally more cardiovascular protection, but 1.0 mg weekly is effective. Titrate to the highest tolerable dose.

Can Ozempic help if you already had a heart attack? Yes. The SELECT trial included patients with prior heart attacks, and the benefit was consistent in this subgroup. Starting semaglutide after a cardiovascular event reduces the risk of a second event by roughly 20% over the following 3 to 4 years.

Should I take Ozempic for heart health if I'm not overweight? The SELECT trial required BMI ≥27, so the proven benefit is in patients with overweight or obesity. For normal-weight patients with cardiovascular disease, traditional medications (statins, ACE inhibitors, beta blockers) have stronger evidence and lower cost. Discuss with your cardiologist.

Does Ozempic help with heart failure? Separate trials are testing semaglutide in heart failure with preserved ejection fraction (HFpEF), with promising early results. For heart failure with reduced ejection fraction (HFrEF), the evidence is mixed and use should be discussed with a cardiologist. Semaglutide is not a standard heart failure treatment.

Can I stop my statin if I start Ozempic? No. Ozempic and statins work through different mechanisms and provide additive benefit. The SELECT trial allowed patients to continue statins, and most did. Stopping a statin to start Ozempic would likely increase cardiovascular risk, not decrease it.

How does Ozempic compare to other GLP-1 medications for heart protection? Liraglutide (Victoza) showed a 13% MACE reduction in the LEADER trial. Dulaglutide (Trulicity) showed a 12% reduction in the REWIND trial. Semaglutide's 20% reduction in SELECT is the largest effect seen in the GLP-1 class, though cross-trial comparisons are imperfect.

Does Ozempic reduce stroke risk? Yes. SUSTAIN-6 showed a 39% reduction in nonfatal stroke in diabetic patients. SELECT showed a 7% reduction in nonfatal stroke in non-diabetic patients, which wasn't statistically significant. The stroke benefit appears stronger in diabetic populations.

What blood tests should I monitor for heart health on Ozempic? Standard cardiovascular monitoring includes lipid panel (LDL, HDL, triglycerides), hemoglobin A1c if diabetic, kidney function (creatinine, eGFR), and liver enzymes. High-sensitivity C-reactive protein (hsCRP) is optional but useful for tracking anti-inflammatory response. Repeat every 3 to 6 months.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
3. Verma S et al. Semaglutide and Inflammation in Obesity without Diabetes: Analysis from SELECT. Circulation. 2024.
4. Arakawa M et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist. Cardiovascular Diabetology. 2010.
5. Lambadiari V et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure. Diabetes Care. 2021.
6. Marso SP et al. Effects of Semaglutide on Progression of Carotid Atherosclerosis. Circulation. 2017.
7. Kosiborod MN et al. Blood Pressure Lowering with Semaglutide: Mechanisms and Clinical Implications. Hypertension. 2024.
8. Ettehad D et al. Blood pressure lowering for prevention of cardiovascular disease and death. Lancet. 2016.
9. Arterburn DE et al. Comparative Effectiveness of Bariatric Surgery vs Medical Therapy for Diabetes and Cardiovascular Outcomes. JAMA. 2021.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
11. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
12. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016.
13. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, Trulicity, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.